YS Biopharma Granted Phase I Clinical Trial License Of Therapeutic Chronic Hepatitis B Virus Vaccine
YS Biopharma Granted Phase I Clinical Trial License Of Therapeutic Chronic Hepatitis B Virus Vaccine
YS Biopharma獲得治療性慢性乙型肝炎病毒疫苗的I期臨床試驗許可
YS Biopharma Co., Ltd. (NASDAQ:YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that its YS-HBV-002 immunotherapeutic vaccine, designed to treat patients suffering from chronic hepatitis B virus ("HBV") infection, has been granted clinical trial approval by the Philippine Food and Drug Administration ("PFDA"). In light of the approval, the Company is preparing to initiate a Phase I clinical trial for YS-HBV-002 in the Philippines, which is expected to begin in June 2024.
YS Biopharma Co., Ltd.（納斯達克股票代碼：YS）（“YS Biopharma” 或 “公司”）是一家致力於發現、開發、製造和交付用於傳染病和癌症的新一代疫苗和治療生物製劑的全球生物製藥公司，今天宣佈，其設計用於治療慢性乙型肝炎病毒（“HBV”）感染患者的 YS-HBV-002 免疫治療疫苗具有已獲得菲律賓食品藥品監督管理局（“PFDA”）的臨床試驗批准。鑑於獲得批准，該公司正準備在菲律賓啓動 YS-HBV-002 的 I 期臨床試驗，該試驗預計於 2024 年 6 月開始。
Chronic HBV infection...
慢性乙...
登入免費觀看全文
登入/註冊